India to South Africa: Ertapenem Export Trade Route

The India to South Africa Ertapenem corridor is one of India's established pharmaceutical export routes, with 17 shipments documented worth a combined $1.8M USD. The route is dominated by EUGIA PHARMA SPECIALITIES LIMITED, which alone accounts for roughly 52% of all export value, reflecting the consolidated nature of India's ertapenem manufacturing sector.

Across 2 active suppliers, the average shipment value stands at $107.0K USD — a figure that reflects both bulk commercial orders from large pharmaceutical companies and smaller specialty shipments. Sea freight dominates at 77% of all shipments, consistent with ertapenem's non-urgent bulk-order profile.

Shipment activity peaks during October–December, with an average transit time of 17 days port-to-port. The route has recorded an annual growth rate of 24.9%, placing it at rank #14 among India's top ertapenem export destinations globally.

On the import side, key buyers of Indian ertapenem in South Africa include AUROGEN SOUTH AFRICA (PTY) LTD,, AUROGEN SOUTH AFRICA (PTY) LTD, , AUROGEN SOUTH AFRICA PTY LTD and 1 others. AUROGEN SOUTH AFRICA (PTY) LTD, is the single largest importer with 5 shipments valued at $533.9K USD.

India's ertapenem exports to South Africa are driven primarily by a handful of large-scale manufacturers. EUGIA PHARMA SPECIALITIES LIMITED with 9 shipments leads the pack, a pattern common in generic pharmaceutical corridors where manufacturing scale creates significant cost advantages. The presence of 2 active exporters signals a competitive but concentrated market — buyers in South Africa benefit from supplier diversity while the top tier handles the majority of volume.

The top 3 suppliers — EUGIA PHARMA SPECIALITIES LIMITED, EUGIA PHARMA SPECIALITIES LIMITED — together account for 100% of total trade value on this route. The average shipment value of $107.0K USD reflects primarily bulk commercial orders from large pharmaceutical distributors.

Beyond the primary product category, shipments on this route include closely related formulations such as ertapenem for injection 1 g/vial (iverz and ertapenem for injection 1 g/vial (iverzam) b.n.2ei25033a, mfg dt 02/2025, exp dt 01/2027, suggesting that buyers in South Africa tend to consolidate orders across related product lines from the same Indian supplier.

On the buying side, AUROGEN SOUTH AFRICA (PTY) LTD, is the largest importer with 5 shipments worth $533.9K USD — representing 29% of all ertapenem imports from India on this route.